Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy

NeuroMolecular Medicine

Volumn 17, Issue 4, 2015, Pages 364-372

  Kalita, Jayantee ^a   Kumar, Vijay ^a   Ranjan, Abhay ^a   Misra, Usha K ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Copper; Glutathione; Lipid peroxidation; Oxidative stress; Total antioxidant capacity; Wilson disease

Indexed keywords

ANTIOXIDANT; CHELATING AGENT; COPPER; GLUTATHIONE; MALONALDEHYDE; PENICILLAMINE; TRIENTINE; TROLOX C; ZINC;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; BLOOD CHEMISTRY; BURKE FAHN MARSDEN SCORE; CHELATION THERAPY; CHILD; CHOREA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; COPPER BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSTONIA; FEMALE; HUMAN; MALE; NEUROLOGIC DISEASE; NEUROLOGIC WILSON DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHOOL CHILD; SCORING SYSTEM; TREMOR; ULTRASOUND; URINE LEVEL; WILSON DISEASE; ADVERSE EFFECTS; BLOOD; COMPARATIVE STUDY; ECHOGRAPHY; HEPATOLENTICULAR DEGENERATION; INTERNATIONAL NORMALIZED RATIO; KIDNEY; LIPID PEROXIDATION; LIVER; METABOLISM; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SPLEEN; TREATMENT OUTCOME; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIOXIDANTS; CHELATING AGENTS; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; COPPER; DISEASE PROGRESSION; FEMALE; GLUTATHIONE; HEPATOLENTICULAR DEGENERATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; KIDNEY; LIPID PEROXIDATION; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PENICILLAMINE; SEVERITY OF ILLNESS INDEX; SPLEEN; TREATMENT OUTCOME; YOUNG ADULT; ZINC;

EID: 84947126667     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-015-8364-8     Document Type: Article

References (45)

1. Brewer, G. J., Askari, F., Dick, R. B., Sitterly, J., Fink, J. K., Carlson, M., et al. (2009). Treatment of Wilson’s disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Translational Research,154(2), 70–77. doi:10.1016/j.trsl.2009.05.002.
2. Brewer, G. J., Askari, F., Lorincz, M. T., Carlson, M., Schilsky, M., Kluin, K. J., et al. (2006). Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Archives of Neurology,63(4), 521–527. doi:10.1001/archneur.63.4.521.
3. Brewer, G. J., Fink, J. K., & Hedera, P. (1999). Diagnosis and treatment of Wilson’s disease. Seminars in Neurology,19(3), 261–270. doi:10.1055/s-2008-1040842.
4. Brewer, G. J., Hedera, P., Kluin, K. J., Carlson, M., Askari, F., Dick, R. B., et al. (2003). Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Archives of Neurology,60(3), 379–385.
5. Brewer, G. J., Terry, C. A., Aisen, A. M., & Hill, G. M. (1987). Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Archives of Neurology,44(5), 490–493.
6. Bruha, R., Marecek, Z., Martasek, P., Nevsimalova, S., Petrtyl, J., Urbanek, P., et al. (2009). Wilson’s disease. Cas Lek Cesk,148(11), 544–548.
7. Bruha, R., Marecek, Z., Pospisilova, L., Nevsimalova, S., Vitek, L., Martasek, P., et al. (2011). Long-term follow-up of Wilson disease: Natural history, treatment, mutations analysis and phenotypic correlation. Liver International,31(1), 83–91. doi:10.1111/j.1478-3231.2010.02354.x.
8. Bruha, R., Vitek, L., Marecek, Z., Pospisilova, L., Nevsimalova, S., Martasek, P., et al. (2012). Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. Journal of Inherited Metabolic Disease,35(3), 541–548. doi:10.1007/s10545-011-9422-5.
9. Bull, P. C., Thomas, G. R., Rommens, J. M., Forbes, J. R., & Cox, D. W. (1993). The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genetics,5(4), 327–337. doi:10.1038/ng1293-327.
10. Chen, D. B., Feng, L., Lin, X. P., Zhang, W., Li, F. R., Liang, X. L., et al. (2012). Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. PLoS One,7(5), e37709. doi:10.1371/journal.pone.0037709.
11. Chen, Y., Vartiainen, N. E., Ying, W., Chan, P. H., Koistinaho, J., & Swanson, R. A. (2001). Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. Journal of Neurochemistry,77(6), 1601–1610.
12. Choi, B. S., & Zheng, W. (2009). Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Research,1248, 14–21. doi:10.1016/j.brainres.2008.10.056.
13. Crum, R. M., Anthony, J. C., Bassett, S. S., & Folstein, M. F. (1993). Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA,269(18), 2386–2391.
14. Das, S. K., & Ray, K. (2006). Wilson’s disease: An update. Nature Clinical Practice Neurology,2(9), 482–493. doi:10.1038/ncpneuro0291.
15. Desagher, S., Glowinski, J., & Premont, J. (1996). Astrocytes protect neurons from hydrogen peroxide toxicity. Journal of Neuroscience,16(8), 2553–2562.
16. Dringen, R., Scheiber, I. F., & Mercer, J. F. (2013). Copper metabolism of astrocytes. Frontiers in Aging Neuroscience,5, 9. doi:10.3389/fnagi.2013.00009.
17. Gaetke, L. M., & Chow, C. K. (2003). Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology,189(1–2), 147–163.
18. Grimm, G., Prayer, L., Oder, W., Ferenci, P., Madl, C., Knoflach, P., et al. (1991). Comparison of functional and structural brain disturbances in Wilson’s disease. Neurology,41(2 (Pt 1)), 272–276.
19. Gromadzka, G., Karpinska, A., Przybylkowski, A., Litwin, T., Wierzchowska-Ciok, A., Dziezyc, K., et al. (2014). Treatment with D-penicillamine or zinc sulphate affects copper metabolism and improves but not normalizes antioxidant capacity parameters in Wilson disease. BioMetals,27(1), 207–215. doi:10.1007/s10534-013-9694-3.
20. Halliwell, B. (2001). Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs and Aging,18(9), 685–716.
21. Janero, D. R. (1990). Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radical Biology and Medicine,9(6), 515–540.
22. Joseph, B., Kapoor, S., Schilsky, M. L., & Gupta, S. (2009). Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model. Hepatology,49(5), 1616–1624. doi:10.1002/hep.22792.
23. Kalita, J., Kumar, V., Chandra, S., Kumar, B., & Misra, U. K. (2014a). Worsening of Wilson disease following penicillamine therapy. European Neurology,71(3–4), 126–131. doi:10.1159/000355276.
24. Kalita, J., Kumar, V., Misra, U. K., Ranjan, A., Khan, H., & Konwar, R. (2014b). A study of oxidative stress, cytokines and glutamate in Wilson disease and their asymptomatic siblings. Journal of Neuroimmunology,274(1–2), 141–148. doi:10.1016/j.jneuroim.2014.06.013.
25. Kalita, J., Somarajan, B. I., Misra, U. K., & Mittal, B. (2010). R778L, H1069Q, and I1102T mutation study in neurologic Wilson disease. Neurology India,58(4), 627–630. doi:10.4103/0028-3886.68678.
26. Koracevic, D., Koracevic, G., Djordjevic, V., Andrejevic, S., & Cosic, V. (2001). Method for the measurement of antioxidant activity in human fluids. Journal of Clinical Pathology,54(5), 356–361.
27. Krystkowiak, P., du Montcel, S. T., Vercueil, L., Houeto, J. L., Lagrange, C., Cornu, P., et al. (2007). Reliability of the Burke–Fahn–Marsden scale in a multicenter trial for dystonia. Movement Disorders,22(5), 685–689. doi:10.1002/mds.21392.
28. Makar, T. K., Nedergaard, M., Preuss, A., Gelbard, A. S., Perumal, A. S., & Cooper, A. J. (1994). Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: Evidence that astrocytes play an important role in antioxidative processes in the brain. Journal of Neurochemistry,62(1), 45–53.
29. Mattie, M. D., & Freedman, J. H. (2001). Protective effects of aspirin and vitamin E (alpha-tocopherol) against copper- and cadmium-induced toxicity. Biochemical and Biophysics Research Communications,285(4), 921–925. doi:10.1006/bbrc.2001.5259.
30. Nagasaka, H., Inoue, I., Inui, A., Komatsu, H., Sogo, T., Murayama, K., et al. (2006). Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: Hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress. Pediatric Research,60(4), 472–477. doi:10.1203/01.pdr.0000238341.12229.d3.
31. Ozcelik, D., & Uzun, H. (2009). Copper intoxication; antioxidant defenses and oxidative damage in rat brain. Biological Trace Element Research,127(1), 45–52. doi:10.1007/s12011-008-8219-3.
32. Ranjan, A., Kalita, J., Kumar, V., & Misra, U. K. (2015). MRI and oxidative stress markers in neurological worsening of Wilson disease following penicillamine. Neurotoxicology,49, 45–49. doi:10.1016/j.neuro.2015.05.004.
33. Reddy, P. V., Rao, K. V., & Norenberg, M. D. (2008). The mitochondrial permeability transition, and oxidative and nitrosative stress in the mechanism of copper toxicity in cultured neurons and astrocytes. Laboratory Investigation,88(8), 816–830. doi:10.1038/labinvest.2008.49.
34. Reed, T. T. (2011). Lipid peroxidation and neurodegenerative disease. Free Radical Biology and Medicine,51(7), 1302–1319. doi:10.1016/j.freeradbiomed.2011.06.027.
35. Roberts, E. A., Schilsky, M. L., & American Association for Study of Liver, D. (2008). Diagnosis and treatment of Wilson disease: An update. Hepatology,47(6), 2089–2111. doi:10.1002/hep.22261.
36. Samuele, A., Mangiagalli, A., Armentero, M. T., Fancellu, R., Bazzini, E., Vairetti, M., et al. (2005). Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson’s disease. Biochimica et Biophysica Acta,1741(3), 325–330. doi:10.1016/j.bbadis.2005.06.004.
37. Scheiber, I. F., & Dringen, R. (2013). Astrocyte functions in the copper homeostasis of the brain. Neurochemistry International,62(5), 556–565. doi:10.1016/j.neuint.2012.08.017.
38. Schosinsky, K. H., Lehmann, H. P., & Beeler, M. F. (1974). Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clinical Chemistry,20(12), 1556–1563.
39. Sokol, R. J., Twedt, D., McKim, J. M, Jr, Devereaux, M. W., Karrer, F. M., Kam, I., et al. (1994). Oxidant injury to hepatic mitochondria in patients with Wilson’s disease and Bedlington terriers with copper toxicosis. Gastroenterology,107(6), 1788–1798.
40. Steinebach, O. M., & Wolterbeek, H. T. (1994). Role of cytosolic copper, metallothionein and glutathione in copper toxicity in rat hepatoma tissue culture cells. Toxicology,92(1–3), 75–90.
41. Stuerenburg, H. J. (2000). CSF copper concentrations, blood–brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson’s disease. J Neural Transm,107(3), 321–329.
42. Summer, K. H., & Eisenburg, J. (1985). Low content of hepatic reduced glutathione in patients with Wilson’s disease. Biochemical Medicine,34(1), 107–111.
43. Thomas, G. R., Forbes, J. R., Roberts, E. A., Walshe, J. M., & Cox, D. W. (1995). The Wilson disease gene: Spectrum of mutations and their consequences. Nature Genetics,9(2), 210–217. doi:10.1038/ng0295-210.
44. Tietze, F. (1969). Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Analytical Biochemistry,27(3), 502–522.
45. Zhang, J. W., Liu, J. X., Hou, H. M., Chen, D. B., Feng, L., Wu, C., et al. (2015). Effects of tetrathiomolybdate and penicillamine on brain hydroxyl radical and free copper levels: A microdialysis study in vivo. Biochemical and Biophysics Research Communications,458(1), 82–85. doi:10.1016/j.bbrc.2015.01.071.